European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · May 2002
Randomized Controlled Trial Clinical TrialNo evidence that amifostine influences the plasma pharmacokinetics of topotecan in ovarian cancer patients.
This aim of this study was to compare the pharmacokinetics of topotecan in the presence and absence of preceding amifostine to reduce the risk of side effects in patients with advanced ovarian cancer. ⋯ Amifostine, 300 mg/m(2), does not significantly affect the pharmacokinetics of topotecan and there are pronounced intra- and inter-individual variabilities in the topotecan pharmacokinetics.